Table 1. Clinical details of patients... | American Society of Hematology

Table 1.

Clinical details of patients with HL and controls

Subject*	Age, y	Sex	Histology	Site	Stage	EBV status	Hb concentration, g/L	WBC count, × 10⁹/L	Lymphocyte count, × 10⁹/L	Albumin concentration, g/L
1	22	F	NS	C	2a	+	119	4.3	1.1	45
2	28	F	NS	C	2a	+	129	12.4	1.6	41
3	29	M	NS	C	2b	-	135	14.1	1.4	49
4	26	M	NS	C	2b	-	105	18.3	1.5	43
5	32	F	NS	C	2b	+	94	43.0	2.3	41
6	62	M	MC	C	4b	+	140	4.9	0.8	42
7	44	M	U†	A	2b	-	128	10.9	1.6	41
8	37	F	NS	C	2b	-	107	11.2	1.5	44
9	21	M	NS	C	2a	-	137	12.0	1.8	43
10	24	M	MC	C	1a	+	134	7.6	2.4	49
11	22	F	NS	C	2b	-	128	13.0	2.9	47
12	48	M	LP	A	1a	-	148	4.6	1.3	41
13	25	M	NS	C	2b	+	118	6.9	1.4	36
14	33	M	NS	C	2a	+	134	6.7	0.6	40
15	30	F	NS†	I	1a	-	153	9.1	2.1	50
16	24	F	NS	C	2a	-	131	9.0	1.3	42
17	19	F	NS	C	2a	-	131	11.9	2.1	42
18	41	F	MC	C	1a	+	136	6.5	1.5	47
19	21	M	NS	A	4b†	-	134	7.7	1.3	46
20	54	M	NS	C	1a†	+	117	5.6	1.2	39
21	20	F	NS	C	2a	-	131	7.1	1.1	42
22	38	M	MC	C	2b	+	150	8.5	2.0	47
23	20	F	NS	C	2a	-	115	13.7	2.2	41
24	27	F	NS	C	2a	-	111	12.6	1.1	43
C1	17	F	Reactive	C	NA	nt	130	9.0	3.3	41
C2	33	F	Reactive	C	NA	nt	154	6.1	1.4	49
C3	20	M	PT	A	NA	nt	150	7.2	2.3	51
C4	53	F	Breast cancer	C	NA	nt	143	9.7	1.6	46
C5	17	F	A-NHL	C	NA	nt	108	6.3	0.6	41

Subject*	Age, y	Sex	Histology	Site	Stage	EBV status	Hb concentration, g/L	WBC count, × 10⁹/L	Lymphocyte count, × 10⁹/L	Albumin concentration, g/L
1	22	F	NS	C	2a	+	119	4.3	1.1	45
2	28	F	NS	C	2a	+	129	12.4	1.6	41
3	29	M	NS	C	2b	-	135	14.1	1.4	49
4	26	M	NS	C	2b	-	105	18.3	1.5	43
5	32	F	NS	C	2b	+	94	43.0	2.3	41
6	62	M	MC	C	4b	+	140	4.9	0.8	42
7	44	M	U†	A	2b	-	128	10.9	1.6	41
8	37	F	NS	C	2b	-	107	11.2	1.5	44
9	21	M	NS	C	2a	-	137	12.0	1.8	43
10	24	M	MC	C	1a	+	134	7.6	2.4	49
11	22	F	NS	C	2b	-	128	13.0	2.9	47
12	48	M	LP	A	1a	-	148	4.6	1.3	41
13	25	M	NS	C	2b	+	118	6.9	1.4	36
14	33	M	NS	C	2a	+	134	6.7	0.6	40
15	30	F	NS†	I	1a	-	153	9.1	2.1	50
16	24	F	NS	C	2a	-	131	9.0	1.3	42
17	19	F	NS	C	2a	-	131	11.9	2.1	42
18	41	F	MC	C	1a	+	136	6.5	1.5	47
19	21	M	NS	A	4b†	-	134	7.7	1.3	46
20	54	M	NS	C	1a†	+	117	5.6	1.2	39
21	20	F	NS	C	2a	-	131	7.1	1.1	42
22	38	M	MC	C	2b	+	150	8.5	2.0	47
23	20	F	NS	C	2a	-	115	13.7	2.2	41
24	27	F	NS	C	2a	-	111	12.6	1.1	43
C1	17	F	Reactive	C	NA	nt	130	9.0	3.3	41
C2	33	F	Reactive	C	NA	nt	154	6.1	1.4	49
C3	20	M	PT	A	NA	nt	150	7.2	2.3	51
C4	53	F	Breast cancer	C	NA	nt	143	9.7	1.6	46
C5	17	F	A-NHL	C	NA	nt	108	6.3	0.6	41

Parameters relevant to the Hasenclever prognostic index²⁶ as well as histologic classification and EBV status as judged by latent membrane protein 1 (LMP1) expression are given. Stage is according to the Ann-Arbor classification.

Hb indicates hemoglobin; WBC, white blood cell; NS, nodular sclerosing; C, cervical; MC, mixed cellularity; U, unclassifiable showing elements of MC and NS; A, axillary; LP, lymphocyte predominant; I,inguinal; NA, not applicable; nt, not tested; PT, progressive transformation of germinal centers; A-NHL, anaplastic non-Hodgkin lymphoma.

The numbers in this column refer to the identifiers in Figures 2, 5, 6 and 7, where regulatory activity is demonstrated.

†

Indicates a relapse.

View Large

This Feature Is Available To Subscribers Only